Zentalis Pharmaceuticals Inc [ZNTL] stock is trading at $2.43, saw in change for the day. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZNTL shares have gain 26.56% over the last week, with a monthly amount drifted -14.74%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] stock has seen the most recent analyst activity on August 12, 2024, when Wedbush upgraded its rating to a Neutral but kept the price target unchanged to $4 for it. Previously, UBS downgraded its rating to Neutral on June 20, 2024, and dropped its price target to $5. On June 18, 2024, downgrade downgraded it’s rating to Equal Weight. Wedbush downgraded its rating to a Underperform and decreased its price target to $4 on June 18, 2024. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $8 on June 18, 2024. Jefferies downgraded its rating to Hold for this stock on June 18, 2024, and downed its price target to $6. In a note dated November 08, 2023, Wedbush downgraded an Neutral rating on this stock and revised its target price from $38 to $12.
Zentalis Pharmaceuticals Inc [ZNTL] stock has fluctuated between $1.61 and $18.07 over the past year. Currently, Wall Street analysts expect the stock to reach $21.86 within the next 12 months. Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] shares were valued at $2.43 at the most recent close of the market. An investor can expect a potential return of 799.59% based on the average ZNTL price forecast.
Analyzing the ZNTL fundamentals
Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -4.91%, Pretax Profit Margin comes in at -4.2%, and Net Profit Margin reading is -4.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.44 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.36 points at the first support level, and at 2.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.54, and for the 2nd resistance point, it is at 2.65.
Ratios To Look Out For
For context, Zentalis Pharmaceuticals Inc’s Current Ratio is 7.29. In addition, the Quick Ratio stands at 7.29 and the Cash Ratio stands at 0.75. Considering the valuation of this stock, the price to sales ratio is 4.27, the price to book ratio is 0.49.
Transactions by insiders
Recent insider trading involved Bruns Ingmar, Chief Medical Officer, that happened on Feb 06 ’25 when 20000.0 shares were purchased. Former Director, Cam Gallagher completed a deal on Feb 11 ’25 to buy 687.0 shares. Meanwhile, PAO and Interim PFO Vultaggio Vincent sold 2615.0 shares on Feb 03 ’25.
